

643,277

"Express Mail" mailing label
Number EL497108525US

Date of Deposit 22 August 2000

I hereby Certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

M. Bud Nelson

Name

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nelson and Barberá-Guillem

B-28

Filed: 22 August 2000

For: Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Assistant Commissioner of Patents
Washington, D.C. 20231

Applicants wish to make of record the following references under the provisions of 37 CFR 1.97 and to provide copies of relevant background cited in the application. The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application, or is to be considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove any document as a cited reference against the claims of the present invention.

References Cited

Please see attached Form PTO-1149 for list of publications, legible copies of all publication listed are enclosed.


Statement of Relevancy

1. U.S. Patent No. 6,080,554; Campine et al. This patent describes methods and compositions for characterizing the activity of multiple sclerosis.
2. Acarin et al., 1996, *Acta Neurol. Scand.* 93:99-103. This paper describes the incidence of antibodies against gangliosides in multiple sclerosis.
3. Sadatipour et al., 1998, *Annals Neurol.* 44:980-983. This paper describes the incidence of antibodies against gangliosides in multiple sclerosis.

5. Barbera-Guillem et al., 1999, *Neoplasia*, 1:453-460.

This paper describes formation of complexes comprising anti-shed tumor antigen (being multivalent for the sTn epitope) and IgG antibody directed thereagainst; and the promotion of inflammation and tissue degradation by the complexes in promoting progression of solid tumors. The pro-tumor immune response described is similar to a pro-MS immune response in both cause and effect.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventors, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)):



M. Bud Nelson
Reg. No. 35,300

BioCrystal Ltd.
575 McCorkle Blvd., Westerville, OH 43082-8888
Date: 22 August 2000